ArticleCase reports in oncology

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.

Go Makimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.